ABSTRACT
We herein report a rare case of a 79-year-old man who presented with the simultaneous occurrence of pancreatic neuroendocrine tumors (PNET) and renal cell carcinomas (RCC), without any other Von Hippel-Lindau (VHL)-associated lesions or any pertinent family history. Computed tomography showed vascular-rich solid lesions in the left kidney and the pancreatic tail, measuring 72 mm and 15 mm in size, respectively. Preoperatively, RCC with pancreatic metastasis was suspected and laparotomy was performed. However, the resected specimens revealed a different tumor histology, namely renal clear cell carcinoma (G2, pT3) and PNET (G1, pT3). The patient and his family refused genetic testing, however, so far, the patient has not developed any VHL-associated lesions for more than four years.
Subject(s)
Adenoma, Islet Cell/complications , Adenoma, Islet Cell/surgery , Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/surgery , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/surgery , von Hippel-Lindau Disease/surgery , Adenoma, Islet Cell/etiology , Aged , Carcinoma, Renal Cell/etiology , Humans , Kidney Neoplasms/complications , Kidney Neoplasms/surgery , Male , Pancreatic Neoplasms/etiology , Pancreatic Neoplasms/pathology , Rare Diseases/diagnosis , Rare Diseases/therapy , Treatment Outcome , von Hippel-Lindau Disease/complicationsABSTRACT
von Hippel-Lindau (VHL) disease, caused by germline mutations in the VHL gene, is a hereditary autosomal-dominant disorder which predisposes the individual to various malignant and benign tumors. VHL acts as a tumor suppressor, mainly through the negative regulation of hypoxia-inducible factors. Molecular-targeted drugs against vascular endothelial growth factor-signaling pathways, a target of hypoxia-inducible factors, have recently been introduced into clinical practice for the treatment of patients with sporadic renal cell carcinoma and pancreatic neuroendocrine tumors. However, whether such treatments are effective in patients with VHL disease remains to be elucidated. We herein report a Japanese patient with VHL disease who was successfully treated with sunitinib for approximately 5 years.
Subject(s)
Adenoma, Islet Cell/drug therapy , Antineoplastic Agents/administration & dosage , Carcinoma, Renal Cell/drug therapy , Indoles/administration & dosage , Kidney Neoplasms/drug therapy , Pancreatic Neoplasms/drug therapy , Pyrroles/administration & dosage , Vascular Endothelial Growth Factor A/antagonists & inhibitors , von Hippel-Lindau Disease/complications , Adenoma, Islet Cell/complications , Adenoma, Islet Cell/diagnosis , Adult , Antineoplastic Agents/pharmacology , Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/diagnosis , Drug Administration Schedule , Fatal Outcome , Genes, Tumor Suppressor/drug effects , Germ-Line Mutation/drug effects , Humans , Indoles/pharmacology , Kidney Neoplasms/complications , Kidney Neoplasms/diagnosis , Male , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/diagnosis , Pyrroles/pharmacology , Signal Transduction/drug effects , Sunitinib , Time FactorsABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Fluorodeoxyglucose F18 , Positron-Emission Tomography/methods , Positron-Emission Tomography , Positron Emission Tomography Computed Tomography , Adenocarcinoma/diagnosis , Adenocarcinoma , Carcinoma, Renal Cell/diagnosis , Carcinoma, Renal Cell , Adrenal Cortex/pathology , Adrenal Cortex , Adrenal Cortex Neoplasms/pathology , Adrenal Cortex Neoplasms , Adrenalectomy/methods , Adenoma, Islet Cell/complications , Adenoma, Islet CellABSTRACT
Pulmonary thromboembolism associated with pancreatic endocrine neoplasia is extremely uncommon in man and animals. Post-mortem examination of an adult owl monkey (Aotus nancymae) revealed extensive pulmonary arterial thromboembolism and a well-demarcated mass attached to the pancreas. Microscopically, the mass consisted of areas of interstitial fibrosis with loss of acini and islets and replacement by nests and sheets of polygonal cells with amphophilic cytoplasm, an eccentric round nucleus with stippled chromatin and, in some cells, with a single prominent eccentric nucleolus. Clusters of these cells were noted within vessels and adjacent lymph nodes. The cells did not express S100 or insulin, but were labelled strongly with SP-1/chromogranin. Rare individual cells expressed glucagon and somatostatin. A few cells in pulmonary thrombi/emboli and the adjacent lymph node also expressed SP-1/chromogranin. Based on cell morphology, location and immunohistochemistry the tumour was classified as pancreatic endocrine (islet cell) carcinoma with metastasis to regional lymph nodes and lung.
Subject(s)
Adenoma, Islet Cell/veterinary , Monkey Diseases/pathology , Pancreatic Neoplasms/veterinary , Pulmonary Embolism/veterinary , Adenoma, Islet Cell/complications , Adenoma, Islet Cell/pathology , Animals , Aotidae , Male , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/pathology , Pulmonary Embolism/etiology , Pulmonary Embolism/pathologyABSTRACT
CONTEXT: Glucagon-like peptide-1 (GLP-1) is a gut peptide that promotes insulin release from pancreatic ß-cells and stimulates ß-cell hyperplasia. GLP-1 secretion causing hypoglycemia has been described once from an ovarian neuroendocrine tumor (NET) but has not been reported from a pancreatic NET (pNET). OBJECTIVE: A 56-yr-old male with a previous diagnosis of diabetes presented with fasting hypoglycemia and was found to have a metastatic pNET secreting glucagon. Neither the primary tumor nor metastases stained for insulin, whereas the resected normal pancreas showed histological evidence of islet cell hyperplasia. We provide evidence that GLP-1 secretion from the tumor was the cause of hyperinsulinemic hypoglycemia. METHODS: GLP-1 levels were determined in the patient, and immunohistochemistry for GLP-1 was performed on the tumor metastases. Ex vivo tissue culture and a bioassay constructed by transplantation of tumor into nude mice were performed to examine the tumor secretory products and their effects on islet cell function. RESULTS: The patient had high levels of glucagon and GLP-1 with an exaggerated GLP-1 response to oral glucose. Immunohistochemistry and primary tissue culture demonstrated secretion of glucagon and GLP-1 from the tumor metastases, whereas insulin secretion was almost undetectable. Ex vivo coculture of the tumor with normal human islets resulted in inhibition of insulin release, and transplanted mice developed impaired glucose tolerance. CONCLUSIONS: This is the first description of glucagon and GLP-1 secretion from a metastatic pNET causing sequential diabetes and hypoglycemia. Hypoglycemia was caused by insulin secretion from hyperplastic ß-cells stimulated by tumor-derived GLP-1.
Subject(s)
Diabetes Mellitus/etiology , Glucagon-Like Peptide 1/blood , Hyperinsulinism/etiology , Hypoglycemia/etiology , Neuroendocrine Tumors/metabolism , Pancreatic Neoplasms/metabolism , Adenoma, Islet Cell/complications , Adenoma, Islet Cell/metabolism , Adenoma, Islet Cell/surgery , Animals , Cells, Cultured , Glucagon/blood , Hepatectomy , Humans , Immunohistochemistry , Male , Mice , Mice, Nude , Middle Aged , Neuroendocrine Tumors/complications , Neuroendocrine Tumors/surgery , Pancreatectomy , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/surgery , Real-Time Polymerase Chain Reaction , SplenectomyABSTRACT
La diabetes mellitus tipo 1 es un síndrome orgánico multisistémico crónico que se caracteriza por un aumento de los niveles de glucosa en la sangre que tiene lugar como resultado de concentraciones bajas de la hormona insulina debido a una eliminación selectiva de las células beta pancreáticas como consecuencia de una respuesta autoinmune aberrante. Los resultados obtenidos con el trasplante de islotes pancreáticos en pacientes con diabetes mellitus tipo 1 han provocado un interés creciente en este campo. Esta técnica precisa de un número importante de islotes pancreáticos para conseguir el objetivo de insulinoindependencia. Así pues, el estudio de estrategias que permitan preservar la masa de células beta en pacientes con diabetes mellitus tipo 1 o generar células beta de novo para su posterior trasplante representa un objetivo de primera necesidad. En este sentido, las estrategias de terapia celular basadas en las células troncales constituyen una alternativa muy esperanzadora(AU)
Diabetes mellitus type 1 is a multisystem chronic organic syndrome characterized by increased blood glucose levels that occur as a result of low concentrations of insulin hormone due to selective elimination of pancreatic beta cells as a consequence of an aberrant autoimmune response. The results of clinical trials based on islet transplantation performed in patients with diabetes mellitus type 1 have greatly increased the interest in this field. This technique requires a significant number of pancreatic islets to achieve the objective of insulin-independence. Thus, the current strategies seek to preserve beta cell mass in patients with diabetes mellitus type 1 or generate de novo beta cells for transplantation. In this regard, cell therapy strategies based on stem cells represent a very promising alternative(AU)
Subject(s)
Humans , Male , Female , Diabetes Mellitus, Type 1/therapy , Cell- and Tissue-Based Therapy/methods , Cell- and Tissue-Based Therapy , Adenoma, Islet Cell/complications , Adenoma, Islet Cell/diagnosis , Cell Differentiation , Cell Differentiation/physiology , Cell- and Tissue-Based Therapy/trends , Exocytosis , Exocytosis/physiology , Stem Cells , Stem Cells/pathologySubject(s)
Adenoma, Islet Cell/surgery , Gastric Bypass/methods , Laparoscopy , Obesity, Morbid/surgery , Pancreatic Neoplasms/surgery , Pancreaticoduodenectomy/methods , Adenoma, Islet Cell/complications , Adenoma, Islet Cell/diagnosis , Biopsy , Diagnosis, Differential , Follow-Up Studies , Humans , Male , Middle Aged , Obesity, Morbid/complications , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/diagnosisABSTRACT
No disponible
No disponible
Subject(s)
Humans , Female , Adult , Adenoma, Islet Cell/complications , Hyperinsulinism/etiologySubject(s)
Adenoma, Islet Cell/complications , Hypoglycemia/etiology , Insulin-Like Growth Factor II/metabolism , Pancreatic Neoplasms/complications , Adenoma, Islet Cell/diagnosis , Adult , Follow-Up Studies , Humans , Hypoglycemia/physiopathology , Hypoglycemia/therapy , Male , Pancreatic Neoplasms/diagnosis , Risk Assessment , Severity of Illness IndexABSTRACT
Insulinoma is considered the most common endocrine tumour of the pancreas with an annual prevalence of 4 cases per million people. Contrary to the other endocrine tumours of this organ, over 90% of the insulinomas are benign in nature. The clinical presentation of this neoplasm depends on excessive production of insulin and pro-insulin and is characterised by the symptoms of neuroglycopenia and catecholamine response. Effective management requires directed biochemical testing, careful choice of preoperative imaging tests, and complete pancreatic exploration by an experienced endocrine surgeon utilising intraoperative ultrasound. The only curative treatment for insulinoma is complete resection of the tumour. The aim of this paper is to critically discuss contemporary diagnosis and treatment of this neoplasm on the basis of progress made in recent years.
Subject(s)
Adenoma, Islet Cell/complications , Adenoma, Islet Cell/diagnosis , Insulinoma/complications , Insulinoma/diagnosis , Pancreatic Neoplasms/diagnosis , Adenoma, Islet Cell/metabolism , Adenoma, Islet Cell/surgery , Diagnosis, Differential , Endocrine Surgical Procedures/methods , Gastrinoma/complications , Gastrinoma/diagnosis , Gastrinoma/metabolism , Gastrinoma/surgery , Humans , Hypoglycemia/complications , Insulin/metabolism , Insulinoma/metabolism , Insulinoma/surgery , Pancreatectomy/methods , Pancreatic Neoplasms/classification , Pancreatic Neoplasms/surgery , Prognosis , Rare DiseasesSubject(s)
Adenoma, Islet Cell/complications , Codon/genetics , Germ-Line Mutation , Multiple Endocrine Neoplasia Type 1/complications , Pancreatic Neoplasms/complications , von Hippel-Lindau Disease/genetics , Adenoma, Islet Cell/diagnosis , Adenoma, Islet Cell/genetics , Adult , Diagnosis, Differential , Female , Humans , Multiple Endocrine Neoplasia Type 1/diagnosis , Multiple Endocrine Neoplasia Type 1/genetics , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/genetics , Tomography, X-Ray Computed , von Hippel-Lindau Disease/complications , von Hippel-Lindau Disease/diagnosisABSTRACT
AIM: To evaluate the ability of the time-signal intensity curve (TIC) of the pancreas obtained from dynamic contrast-enhanced magnetic resonance imaging (MRI) for differentiation of focal pancreatic masses, especially pancreatic carcinoma coexisting with chronic pancreatitis and tumor-forming pancreatitis. METHODS: Forty-eight consecutive patients who underwent surgery for a focal pancreatic mass, including pancreatic ductal carcinoma (n=33), tumor-forming pancreatitis (n=8), and islet cell tumor (n=7), were reviewed. Five pancreatic carcinomas coexisted with longstanding chronic pancreatitis. The pancreatic TICs were obtained from the pancreatic mass and the pancreatic parenchyma both proximal and distal to the mass lesion in each patient, prior to surgery, and were classified into 4 types according to the time to a peak: 25 s and 1, 2, and 3 min after the bolus injection of contrast material, namely, type-I, II, III, and IV, respectively, and were then compared to the corresponding histological pancreatic conditions. RESULTS: Pancreatic carcinomas demonstrated type-III (n=13) or IV (n=20) TIC. Tumor-forming pancreatitis showed type-II (n=5) or III (n=3) TIC. All islet cell tumors revealed type-I. The type-IV TIC was only recognized in pancreatic carcinoma, and the TIC of carcinoma always depicted the slowest rise to a peak among the 3 pancreatic TICs measured in each patient, even in patients with chronic pancreatitis. CONCLUSION: Pancreatic TIC from dynamic MRI provides reliable information for distinguishing pancreatic carcinoma from other pancreatic masses, and may enable us to avoid unnecessary pancreatic surgery and delays in making a correct diagnosis of pancreatic carcinoma, especially, in patients with longstanding chronic pancreatitis.
Subject(s)
Magnetic Resonance Imaging/methods , Pancreatic Neoplasms/complications , Pancreatic Neoplasms/diagnosis , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/etiology , Adenoma, Islet Cell/complications , Adenoma, Islet Cell/diagnosis , Adenoma, Islet Cell/pathology , Aged , Aged, 80 and over , Diagnosis, Differential , Female , Humans , Insulinoma/complications , Insulinoma/diagnosis , Insulinoma/pathology , Male , Middle Aged , Pancreas/pathology , Pancreatic Neoplasms/pathology , Pancreatitis, Chronic/pathology , Retrospective StudiesABSTRACT
Congenital hyperinsulinism (HI) exists in 2 histologic forms, focal and diffuse, and rarely has been attributed to lesions in ectopic pancreatic tissue. The ability to distinguish focal from diffuse HI and locate focal lesions has been difficult, thus limiting the optimal management of HI. We present a case of HI resulting from focal pancreatic and ectopic pancreatic lesions. After a near-total pancreatectomy failed to improve the patient's condition, a positron emission tomography (PET) scan performed with 18F-fluoro-L-dihydroxyphenylalanine demonstrated a focal lesion remaining in the head of the pancreas as well as 4 hot spots inferior to the remaining pancreas. Surgical exploration found pancreatic rests in the jejunum responsible for the hot spots seen on PET. Resection of the remainder of the pancreas as well as the small intestinal lesions resulted in correction of the patient's HI. Pathology confirmed the presence of focal HI lesions in the pancreatic head and small intestinal specimens. This case supports the ability of ectopic pancreatic tissue to contribute to the pathology of HI. It highlights the ability of PET to successfully identify focal lesions, including ectopic tissue, responsible for hyperinsulinemic hypoglycemia.
Subject(s)
Adenoma, Islet Cell/diagnosis , Congenital Hyperinsulinism/diagnosis , Jejunal Neoplasms/diagnosis , Pancreatic Neoplasms/diagnosis , Adenoma, Islet Cell/complications , Congenital Hyperinsulinism/etiology , Female , Humans , Infant , Jejunal Neoplasms/complications , Pancreatic Neoplasms/complications , Positron-Emission TomographySubject(s)
Adenoma, Islet Cell/complications , Multiple Endocrine Neoplasia Type 1/complications , Pancreatic Neoplasms/complications , von Hippel-Lindau Disease/complications , Adenoma, Islet Cell/genetics , Adenoma, Islet Cell/pathology , DNA Mutational Analysis , Genetic Predisposition to Disease , Humans , Multiple Endocrine Neoplasia Type 1/genetics , Multiple Endocrine Neoplasia Type 1/pathology , Mutation , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , von Hippel-Lindau Disease/genetics , von Hippel-Lindau Disease/pathologyABSTRACT
We report a case of an elderly gentleman with renal cell carcinoma presenting with the rare entity of non-islet cell tumor hypoglycemia (NICTH). Non-islet cell tumor hypoglycemia syndrome is caused by the tumor producing insulin-like growth factor II, causing hypoglycemia. The syndrome is most commonly associated with very large fibromas or fibrosarcomas.
Subject(s)
Adenoma, Islet Cell/complications , Carcinoma, Renal Cell/complications , Hypoglycemia/etiology , Kidney Neoplasms/complications , Pancreatic Neoplasms/complications , Adenoma, Islet Cell/blood , Adenoma, Islet Cell/pathology , Aged, 80 and over , Carcinoma, Renal Cell/pathology , Diagnosis, Differential , Humans , Hypoglycemia/blood , Hypoglycemia/pathology , Insulin-Like Growth Factor I/metabolism , Insulin-Like Growth Factor II/metabolism , Kidney Neoplasms/pathology , Male , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/pathologyABSTRACT
Acrochordons are frequently encountered benign skin lesions that may occasionally represent underlying pathology. Pancreatic islet-cell tumors are rare neoplasms and few cases have been described in patients with tuberous sclerosis complex (TSC). A 39-year-old man presenting in acute renal failure was referred to us for further diagnostic evaluation of coincidentally noted dysmorphic features. Physical examination revealed over 1,000 acrochordons in addition to findings meeting criteria for TSC. The diagnosis was confirmed by disclosure of mutation in the TSC2 gene. Further evaluation revealed pancreatic islet cell tumors. Acrochordons are a common skin lesion, but when presenting in an atypical manner or unusual number may be a sign of TSC and underlying occult pathology thereby warranting evaluation of TSC2. Additionally, mutations in TSC2 gene may be a risk factor for developing pancreatic islet-cell tumors.
Subject(s)
Adenoma, Islet Cell/genetics , Adenoma, Islet Cell/pathology , Mutation , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/pathology , Skin Diseases/genetics , Tuberous Sclerosis/genetics , Tumor Suppressor Proteins/genetics , Adenoma, Islet Cell/complications , Adult , Female , Humans , Male , Pancreatic Neoplasms/complications , Pedigree , Renal Insufficiency/diagnosis , Renal Insufficiency/genetics , Skin Diseases/complications , Tuberous Sclerosis/complications , Tuberous Sclerosis Complex 2 ProteinABSTRACT
The hormonal interactions among the systems throughout the body are not fully understood; many vague clinical symptoms may in fact be manifestations of underlying endocrine diseases. The aim of the following review is to discuss gastrointestinal manifestations of surgically correctable endocrine diseases, focusing on abnormalities of thyroid function, cancer and finally autoimmune diseases. We also review manifestations of pancreatic endocrine tumors, and multiple endocrine neoplasia.
Subject(s)
Endocrine System Diseases/complications , Gastrointestinal Diseases/etiology , Gastrointestinal Tract/physiopathology , Adenoma, Islet Cell/complications , Adenoma, Islet Cell/diagnosis , Adenoma, Islet Cell/physiopathology , Adenoma, Islet Cell/surgery , Endocrine System Diseases/diagnosis , Endocrine System Diseases/physiopathology , Endocrine System Diseases/surgery , Gastrointestinal Diseases/physiopathology , Humans , Neuroendocrine Tumors/complications , Neuroendocrine Tumors/diagnosis , Neuroendocrine Tumors/physiopathology , Neuroendocrine Tumors/surgery , Thyroid Diseases/complications , Thyroid Diseases/diagnosis , Thyroid Diseases/physiopathology , Thyroid Diseases/surgeryABSTRACT
It has been suggested that microadenomatosis of the endocrine pancreas is a hallmark of the multiple endocrine neoplasia type 1 syndrome (MEN1). This study attempts to elucidate the relationship between pancreatic microadenomatosis and the MEN1 and von Hippel-Lindau (VHL) syndromes. Pancreatic tissue specimens from 37 patients (with either microadenomatosis or the MEN1 syndrome) were analyzed using immunohistochemistry, confocal laser scanning microscopy, and morphometric methods. The MEN1 and the VHL status were assessed on the basis of clinical criteria (all patients) and PCR-based mutational analysis (15 and 5 patients, respectively). Pancreatic microadenomatosis was found in 35 of 37 patients, 28 of whom fulfilled the clinicopathologic criteria and 13 the genetic criteria for MEN1, whereas none of the patients had evidence of a VHL syndrome. Microadenomas were present in 26 of the 28 MEN1 patients, and all these tumors were consistently multihormonal. Five of the 9 patients with microadenomatosis and no clinical evidence for MEN1 or VHL also lacked mutations for the respective genes. Five of these 9 patients suffered from hyperinsulinism and revealed multiple insulin-positive tumors. The other patients were nonsymptomatic and showed multiple glucagon-expressing neoplasms. In microadenomatosis patients with and without the MEN1 syndrome, a subset of morphologically normal-appearing islets showed increased endocrine cell proliferation. In conclusion, endocrine multihormonal microadenomatosis of the pancreas is a feature of MEN1. In addition, a monohormonal type of pancreatic microadenomatosis was identified that consisted of either insulinomas or glucagon-producing tumors and was not associated with MEN1 or VHL.